Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS

(PresseBox) ( Zurich, Switzerland, and Milan, Italy, )
Nycomed, a privately owned global pharmaceutical company, and Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that Eurand has entered into an exclusive commercialization, license and supply agreement with Nycomed for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial terms were not disclosed.

Under the agreement, Nycomed Russia-CIS will market and distribute ZENPEP® (pancrelipase) Delayed-Release Capsules in Russia and CIS, as well as Georgia and Mongolia, subject to regulatory review and approval of the product in those territories. ZENPEP is an FDA-approved pancreatic enzyme product (PEP) indicated for the treatment of pancreatic insufficiency in patients with cystic fibrosis or other conditions, such as chronic pancreatitis, gastrointestinal surgery and pancreatic cancer. Eurand markets ZENPEP directly in the U.S. through its own sales force.

"This agreement represents an important development in our international marketing strategy for ZENPEP," said Andrew Thompson, Eurand's Vice President, Commercial Operations. "Nycomed is one of the fastest-growing pharmaceutical companies in Russia, and we are very confident of their ability to maximize the value of ZENPEP in that market. We look forward to working with Nycomed in pursuing regulatory approval for this product in the important Russia-CIS region."

"Nycomed is excited at the prospect of launching ZENPEP into the Russia-CIS market, where we are launching our recently established gastrointestinal product portfolio," said Jostein Davidson, Senior Vice President, Nycomed Group, and President, Nycomed Russia-CIS. "We believe ZENPEP, which has been specifically formulated to meet the FDA's stringent guidelines for PEPs, will offer physicians an important new treatment option for their patients with pancreatic insufficiency."

Russia-CIS is a significant market for PEPs, which is dominated by digestive disorders such as chronic pancreatitis. According to data provided by IMS Health Incorporated, the PEP market in this region was estimated to be approximately EUR 93.5 million ($130.5 million) in 2009.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking/

orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.